Amedeo Smart

Free Medical Literature Service

 

Amedeo

Dermatology
  Free Subscription

Articles published in
Cancer Lett
    August 2024
  1. FLETCHER K, Cortellini A, Ganta T, Kankaria R, et al
    Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
    Cancer Lett. 2024;596:217001.
    >> Share

  2. KIM YJ, Lee M, Kim EH, Lee S, et al
    Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
    Cancer Lett. 2024;596:216998.
    >> Share

    July 2024
  3. LI M, Zhang L, Guan T, Huang L, et al
    Energy stress-activated AMPK phosphorylates Snail1 and suppresses its stability and oncogenic function.
    Cancer Lett. 2024;595:216987.
    >> Share

  4. LIU M, Zhao Z, Wang C, Sang S, et al
    Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells.
    Cancer Lett. 2024;594:216991.
    >> Share

  5. FU Z, Zhang L, Chen R, Zhan J, et al
    Biphasic co-detection of melanoma aneuploid tumor cells and tumor endothelial cells in guidance of specifying the field cancerized surgical excision margin and administering immunotherapy.
    Cancer Lett. 2024;598:217099.
    >> Share

    June 2024
  6. LIAO Q, Shi H, Yang J, Ge S, et al
    FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m(6)A modifications of multiple pro-angiogenic factors.
    Cancer Lett. 2024;592:216911.
    >> Share

  7. RIVERA-RAMOS A, Cruz-Hernandez L, Talaveron R, Sanchez-Montero MT, et al
    Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth.
    Cancer Lett. 2024;591:216879.
    >> Share

    May 2024
  8. SONG Y, Ren S, Chen X, Li X, et al
    Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by disrupting aberrant mitochondrial fusion dynamics.
    Cancer Lett. 2024;590:216847.
    >> Share

  9. LV Y, Sun S, Zhang J, Wang C, et al
    Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of IRF7 to promote IFNB1 transcription.
    Cancer Lett. 2024 May 24:216988. doi: 10.1016/j.canlet.2024.216988.
    >> Share

  10. WANG J, Hirose H, Du G, Chong K, et al
    Corrigendum to "P-REX1 amplification promotes progression of cutaneous melanomavia the PAK1/P38/MMP-2 pathway" [Cancer Lett. 407 (2017) 66-75].
    Cancer Lett. 2024 May 23:216966. doi: 10.1016/j.canlet.2024.216966.
    >> Share

  11. LIN Z, Chen L, Wang Y, Zhang T, et al
    Improving Ultrasound Diagnostic Precision for Breast Cancer and Adenosis with Modality-Specific Enhancement (MSE) - Breast Net.
    Cancer Lett. 2024 May 23:216977. doi: 10.1016/j.canlet.2024.216977.
    >> Share

  12. BELLI S, Esposito D, Ascione CM, Messina F, et al
    EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Cancer Lett. 2024 May 22:216968. doi: 10.1016/j.canlet.2024.216968.
    >> Share

    April 2024
  13. ZHANG Y, Tan Y, Yuan J, Tang H, et al
    circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer.
    Cancer Lett. 2024;592:216907.
    >> Share

  14. JIA Y, Zhang F, Meng X, Andreev D, et al
    Osteocytes support bone metastasis of melanoma cells by CXCL5.
    Cancer Lett. 2024 Apr 6:216866. doi: 10.1016/j.canlet.2024.216866.
    >> Share

  15. WANG L, Liu X, Han Y, Tsai HI, et al
    TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.
    Cancer Lett. 2024 Apr 5:216861. doi: 10.1016/j.canlet.2024.216861.
    >> Share

  16. LI K, Lin H, Liu A, Qiu C, et al
    SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
    Cancer Lett. 2024;590:216842.
    >> Share

  17. WANG J, Fan P, Shen P, Fan C, et al
    XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer.
    Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846.
    >> Share

  18. ORHAN E, Velazquez C, Tabet I, Fenou L, et al
    CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Cancer Lett. 2024 Apr 2:216820. doi: 10.1016/j.canlet.2024.216820.
    >> Share

  19. BULLOCK KK, Shattuck-Brandt R, Scalise C, Luo W, et al
    Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
    Cancer Lett. 2024;586:216681.
    >> Share

    March 2024
  20. YANG Z, Chen H, Yin S, Mo H, et al
    PGR-KITLG signaling drives a tumor-mast cell regulatory feedback to modulate apoptosis of breast cancer cells.
    Cancer Lett. 2024 Mar 29:216795. doi: 10.1016/j.canlet.2024.216795.
    >> Share

  21. IDRISS MH, Stull CM, Migden MR
    Treatments on the horizon for locally advanced basal cell carcinoma.
    Cancer Lett. 2024;589:216821.
    >> Share

  22. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
    Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
    Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
    >> Share

  23. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
    Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Cancer Lett. 2024;584:216608.
    >> Share

    February 2024
  24. WANG X, Deng X, Hu J, Zheng W, et al
    K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 29:216764. doi: 10.1016/j.canlet.2024.216764.
    >> Share

  25. SUN J, Du R, Li X, Liu C, et al
    CD63(+) cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20.
    Cancer Lett. 2024 Feb 23:216747. doi: 10.1016/j.canlet.2024.216747.
    >> Share

  26. HAN BY, Chen C, Luo H, Lin CJ, et al
    Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.
    Cancer Lett. 2024 Feb 23:216763. doi: 10.1016/j.canlet.2024.216763.
    >> Share

  27. MURTHY D, Dutta D, Attri KS, Samanta T, et al
    CD24 negativity reprograms mitochondrial metabolism to PPARalpha and NF-kappaB-driven fatty acid beta-oxidation in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 17:216724. doi: 10.1016/j.canlet.2024.216724.
    >> Share

  28. XIONG H, Zhai Y, Meng Y, Wu Z, et al
    Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarization.
    Cancer Lett. 2024 Feb 13:216732. doi: 10.1016/j.canlet.2024.216732.
    >> Share

  29. MIRZAEI H, Salehi H, Oskuee RK, Mohammadpour A, et al
    Retraction notice to "The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model" [Cancer Lett. 419 (2018) 30-39].
    Cancer Lett. 2024 Feb 2:216670. doi: 10.1016/j.canlet.2024.216670.
    >> Share

  30. BAHREYNI A, Mohamud Y, Luo H
    Oncolytic virus-based combination therapy in breast cancer.
    Cancer Lett. 2024 Feb 1:216634. doi: 10.1016/j.canlet.2024.216634.
    >> Share

  31. TAN Z, Boyapati K, Tressler CM, Jenkinson N, et al
    Glutamine transporter SLC38A3 promotes breast cancer metastasis via Gsk3beta/beta-catenin/EMT pathway.
    Cancer Lett. 2024 Feb 1:216653. doi: 10.1016/j.canlet.2024.216653.
    >> Share

    January 2024
  32. ZHANG J, Joshua AM, Yue L, O'Meara CH, et al
    Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma.
    Cancer Lett. 2024 Jan 26:216633. doi: 10.1016/j.canlet.2024.216633.
    >> Share

  33. CHEN SY, Zhang FL, Zhang YL, Liao L, et al
    Spermatid perinuclear RNA-binding protein promotes UBR5-mediated proteolysis of Dicer to accelerate triple-negative breast cancer progression.
    Cancer Lett. 2024 Jan 25:216672. doi: 10.1016/j.canlet.2024.216672.
    >> Share

  34. LIU C, Qian X, Yu C, Xia X, et al
    Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-alpha signaling axis in triple-negative breast cancer.
    Cancer Lett. 2024 Jan 24:216642. doi: 10.1016/j.canlet.2024.216642.
    >> Share

  35. JIA F, Sun S, Li J, Wang W, et al
    Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing.
    Cancer Lett. 2024 Jan 22:216656. doi: 10.1016/j.canlet.2024.216656.
    >> Share

  36. LIU C, Cheng X, Han K, Hong L, et al
    A novel molecular subtyping based on multi-omics analysis for prognosis predicting in colorectal melanoma: A 16-year prospective multicentric study.
    Cancer Lett. 2024 Jan 19:216663. doi: 10.1016/j.canlet.2024.216663.
    >> Share

  37. CHEN L, Xu G, Song X, Zhang L, et al
    A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation.
    Cancer Lett. 2024 Jan 16:216635. doi: 10.1016/j.canlet.2024.216635.
    >> Share

    December 2023
  38. ZHONG W, Jian Y, Zhang C, Li Y, et al
    SHC4 orchestrates beta-catenin pathway-mediated metastasis in triple-negative breast cancer by promoting Src kinase autophosphorylation.
    Cancer Lett. 2023 Dec 3:216516. doi: 10.1016/j.canlet.2023.216516.
    >> Share

  39. LEI X, Liao R, Chen X, Wang Z, et al
    IMPA2 promotes basal-like breast cancer aggressiveness by a MYC-mediated positive feedback loop.
    Cancer Lett. 2023 Dec 2:216527. doi: 10.1016/j.canlet.2023.216527.
    >> Share

    November 2023
  40. GUO H, Tan YQ, Huang X, Zhang S, et al
    Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma.
    Cancer Lett. 2023;579:216443.
    >> Share

  41. WU S, Lu J, Zhu H, Wu F, et al
    A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer.
    Cancer Lett. 2023;581:216508.
    >> Share

  42. XIAO Q, Xia M, Tang W, Zhao H, et al
    The lipid metabolism remodeling: A hurdle in breast cancer therapy.
    Cancer Lett. 2023 Nov 28:216512. doi: 10.1016/j.canlet.2023.216512.
    >> Share

  43. CERDIDO S, Abrisqueta M, Sanchez-Beltran J, Lambertos A, et al
    MGRN1 depletion promotes intercellular adhesion in melanoma by upregulation of E-cadherin and inhibition of CDC42.
    Cancer Lett. 2023;581:216484.
    >> Share

  44. HU X, Hu Z, Zhang H, Zhang N, et al
    Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses.
    Cancer Lett. 2023 Nov 7:216466. doi: 10.1016/j.canlet.2023.216466.
    >> Share

    September 2023
  45. MORTAJA M, Demehri S
    Skin cancer prevention - Recent advances and unmet challenges.
    Cancer Lett. 2023 Sep 19:216406. doi: 10.1016/j.canlet.2023.216406.
    >> Share

  46. XU M, Li S
    Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment.
    Cancer Lett. 2023 Sep 18:216397. doi: 10.1016/j.canlet.2023.216397.
    >> Share

    August 2023
  47. ZHANG X, Guo H, Chen J, Xu C, et al
    Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
    Cancer Lett. 2023 Aug 17:216355. doi: 10.1016/j.canlet.2023.216355.
    >> Share

    July 2023
  48. ZHANG X, Hu Z, Wang X, Li L, et al
    Corrigendum to "ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation" [Cancer Lett. 519 (2021) 237-249].
    Cancer Lett. 2023 Jul 18:216310. doi: 10.1016/j.canlet.2023.216310.
    >> Share

  49. TER STEEGE EJ, Doornbos LW, Haughton PD, van Diest PJ, et al
    R-spondin-3 promotes proliferation and invasion of breast cancer cells independently of Wnt signaling.
    Cancer Lett. 2023 Jul 3:216301. doi: 10.1016/j.canlet.2023.216301.
    >> Share

    May 2023
  50. REN Z, Xue Y, Liu L, Zhang X, et al
    Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function.
    Cancer Lett. 2023 May 14:216221. doi: 10.1016/j.canlet.2023.216221.
    >> Share

    March 2023
  51. ZHAO J, Gao N, Xu J, Zhu X, et al
    Novel strategies in melanoma treatment using silver nanoparticles.
    Cancer Lett. 2023 Mar 27:216148. doi: 10.1016/j.canlet.2023.216148.
    >> Share

  52. ZHANG Y, Chen J, Mi D, Ling J, et al
    Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFbeta signaling pathway.
    Cancer Lett. 2023;560:216142.
    >> Share

  53. DENG L, Liao L, Zhang YL, Hu SY, et al
    MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression.
    Cancer Lett. 2023 Mar 10:216124. doi: 10.1016/j.canlet.2023.216124.
    >> Share

  54. MA J, Zhu J, Li J, Liu J, et al
    Enhanced E6AP-mediated ubiquitination of ENO1 via LINC00663 contributes to radiosensitivity of breast cancer by regulating mitochondrial homeostasis.
    Cancer Lett. 2023 Mar 3:216118. doi: 10.1016/j.canlet.2023.216118.
    >> Share

    February 2023
  55. BERG AL, Showalter MR, Kosaisawe N, Hu M, et al
    Cellular transformation promotes the incorporation of docosahexaenoic acid into the endolysosome-specific lipid bis(monoacylglycerol)phosphate in breast cancer.
    Cancer Lett. 2023;557:216090.
    >> Share

  56. GANDULLO-SANCHEZ L, Pandiella A
    An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs.
    Cancer Lett. 2023;554:216024.
    >> Share

    January 2023
  57. WANG L, Mi D, Hu J, Liu W, et al
    A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer.
    Cancer Lett. 2023;555:216049.
    >> Share

    December 2022
  58. DENG S, Banerjee S, Chen H, Pochampally S, et al
    SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
    Cancer Lett. 2022 Dec 31:216046. doi: 10.1016/j.canlet.2022.216046.
    >> Share

  59. LEE Y, Graham P, Li Y
    Extracellular vesicles as a novel approach for breast cancer therapeutics.
    Cancer Lett. 2022 Dec 12:216036. doi: 10.1016/j.canlet.2022.216036.
    >> Share

    October 2022
  60. DU Y, Cai Y, Lv Y, Zhang L, et al
    Single-cell RNA sequencing unveils the communications between malignant T and myeloid cells contributing to tumor growth and immunosuppression in cutaneous T-cell lymphoma.
    Cancer Lett. 2022 Oct 17:215972. doi: 10.1016/j.canlet.2022.215972.
    >> Share

  61. PALAZZO A, Hernandez-Vargas H, Goehrig D, Medard JJ, et al
    Transformed cells after senescence give rise to more severe tumor phenotypes than transformed non-senescent cells.
    Cancer Lett. 2022;546:215850.
    >> Share

  62. XIE XF, Wu NQ, Wu JF, Zhang GL, et al
    CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944.
    >> Share

  63. LUO Y, Tang W, Xiang S, Feng J, et al
    Non-coding RNAs in breast cancer: Implications for programmed cell death.
    Cancer Lett. 2022 Oct 3:215929. doi: 10.1016/j.canlet.2022.215929.
    >> Share

  64. HUANG CP, Liu LC, Chang CC, Wu CC, et al
    Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models.
    Cancer Lett. 2022;545:115478.
    >> Share

    September 2022
  65. LUO M, Li J, Yang Q, Xu S, et al
    N4BP3 promotes breast cancer metastasis via NEDD4-mediated E-cadherin ubiquitination and degradation.
    Cancer Lett. 2022 Sep 23:215926. doi: 10.1016/j.canlet.2022.215926.
    >> Share

  66. LI T, Zhai D, Zhang M, Ye R, et al
    KIF17 maintains the epithelial phenotype of breast cancer cells and curbs tumour metastasis.
    Cancer Lett. 2022 Sep 8:215904. doi: 10.1016/j.canlet.2022.215904.
    >> Share

  67. LIU X, Zhang G, Yu T, He J, et al
    Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis.
    Cancer Lett. 2022;543:215781.
    >> Share

    August 2022
  68. ZHANG T, Huang P
    Response to letter to the editor regarding "Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer".
    Cancer Lett. 2022 Aug 23:215881. doi: 10.1016/j.canlet.2022.215881.
    >> Share

  69. WANG M, Wei R, Li G, Bi HL, et al
    SUMOylation of SYNJ2BP-COX16 promotes breast cancer progression through DRP1-mediated mitochondrial fission.
    Cancer Lett. 2022 Aug 20:215871. doi: 10.1016/j.canlet.2022.215871.
    >> Share

  70. WANG Y, Zhou X, Lei Y, Chu Y, et al
    NNMT contributes to high metastasis of triple negative breast cancer by enhancing PP2A/MEK/ERK/c-Jun/ABCA1 pathway mediated membrane fluidity.
    Cancer Lett. 2022;547:215884.
    >> Share

  71. BAHREYNI A, Liu H, Mohamud Y, Xue YC, et al
    A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
    Cancer Lett. 2022 Aug 19:215849. doi: 10.1016/j.canlet.2022.215849.
    >> Share

  72. LIANG Y, Zhou X, Xie Q, Sun H, et al
    CD146 interaction with integrin beta1 activates LATS1-YAP signaling and induces radiation-resistance in breast cancer cells.
    Cancer Lett. 2022;546:215856.
    >> Share

    July 2022
  73. DU Z, Feng Y, Zhang H, Liu J, et al
    Melanoma-derived small extracellular vesicles remodel the systemic onco-immunity via disrupting hematopoietic stem cell proliferation and differentiation.
    Cancer Lett. 2022 Jul 31:215841. doi: 10.1016/j.canlet.2022.215841.
    >> Share

  74. RODRIGUES-FERREIRA S, Nahmias C
    Predictive biomarkers for personalized medicine in breast cancer.
    Cancer Lett. 2022;545:215828.
    >> Share

  75. PERDRIX ROSELL A, Maiques O, Martin JAJ, Chakravarty P, et al
    Early functional mismatch between breast cancer cells and their tumour microenvironment suppresses long term growth.
    Cancer Lett. 2022 Jul 5:215800. doi: 10.1016/j.canlet.2022.215800.
    >> Share

    June 2022
  76. ZHAI D, Zhang M, Li Y, Bi J, et al
    LINC01194 recruits NUMA1 to promote ubiquitination of RYR2 to enhance malignant progression in triple-negative breast cancer.
    Cancer Lett. 2022 Jun 21:215797. doi: 10.1016/j.canlet.2022.215797.
    >> Share

  77. MEHLICH D, Marusiak AA
    Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Cancer Lett. 2022 Jun 3:215775. doi: 10.1016/j.canlet.2022.215775.
    >> Share

    May 2022
  78. YUE P, Zhu Y, Brotherton-Pleiss C, Fu W, et al
    Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
    Cancer Lett. 2022;534:215613.
    >> Share

  79. LAW ME, Yaaghubi E, Ghilardi AF, Davis BJ, et al
    Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.
    Cancer Lett. 2022;534:215604.
    >> Share

  80. GOBEL A, Riffel RM, Hofbauer LC, Rachner TD, et al
    The mevalonate pathway in breast cancer biology.
    Cancer Lett. 2022 May 28:215761. doi: 10.1016/j.canlet.2022.215761.
    >> Share

  81. LAURIN KM, Coutu-Beaudry K, Salazar A, Meribout N, et al
    Low expression of PGC-1beta and other mitochondrial biogenesis modulators in melanoma is associated with growth arrest and the induction of an immunosuppressive gene expression program dependent on MEK and IRF-1.
    Cancer Lett. 2022 May 17:215738. doi: 10.1016/j.canlet.2022.215738.
    >> Share

  82. SIRKISOON SR, Wong GL, Aguayo NR, Doheny DL, et al
    Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2-->CNTF axis to promote progression of brain metastases.
    Cancer Lett. 2022 May 16:215726. doi: 10.1016/j.canlet.2022.215726.
    CNTF axis to promote progression of brain metastases.&body=SIRKISOON SR, Wong GL, Aguayo NR, Doheny DL, et al. Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2-->CNTF axis to promote progression of brain metastases. Cancer Lett. 2022 May 16:215726. doi: 10.1016/j.canlet.2022.215726. https://www.ncbi.nlm.nih.gov/m/pubmed/35589002" ALT="Email" TITLE="Email"> --> >> Share

  83. TIMILSINA S, Rajamanickam S, Rao AD, Subbarayalu P, et al
    The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.
    Cancer Lett. 2022 May 11:215717. doi: 10.1016/j.canlet.2022.215717.
    >> Share

    April 2022
  84. MA S, Zhang J, Guo Q, Cao C, et al
    Disrupting PHF8-TOPBP1 connection elicits a breast tumor-specific vulnerability to chemotherapeutics.
    Cancer Lett. 2022;530:29-44.
    >> Share

    March 2022
  85. YU S, Li W, Tang L, Fan X, et al
    Depression in breast cancer patients: Immunopathogenesis and immunotherapy.
    Cancer Lett. 2022;536:215648.
    >> Share

  86. LIU Y, Zhang Z, Gao X, Ma Q, et al
    Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B.
    Cancer Lett. 2022 Mar 9:215629. doi: 10.1016/j.canlet.2022.215629.
    >> Share

  87. DU G, Sun J, Li Z, Zhang Q, et al
    A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer.
    Cancer Lett. 2022 Mar 5:215618. doi: 10.1016/j.canlet.2022.215618.
    >> Share

  88. LYU X, Zhang Q, Fares HM, Wang Y, et al
    Contribution of adipocytes in the tumor microenvironment to breast cancer metabolism.
    Cancer Lett. 2022;534:215616.
    >> Share

    February 2022
  89. SCHREIBER C, Gruber A, Rosswag S, Saraswati S, et al
    Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis.
    Cancer Lett. 2022 Feb 15:215600. doi: 10.1016/j.canlet.2022.215600.
    >> Share

    January 2022
  90. SOTO-GAMEZ A, Wang Y, Zhou X, Seras L, et al
    Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
    Cancer Lett. 2022;525:67-75.
    >> Share

  91. CHAIB M, Sipe LM, Yarbro JR, Bohm MS, et al
    PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8(+) T cells in breast cancer.
    Cancer Lett. 2022 Jan 21. pii: S0304-3835(22)00025.
    >> Share

  92. MISHRA A, Hourigan D, Lindsay AJ
    Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.
    Cancer Lett. 2022;529:153-167.
    >> Share

  93. HOUBEN R, Hesbacher S, Sarma B, Schulte C, et al
    Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth.
    Cancer Lett. 2022;524:259-267.
    >> Share

  94. PENG Y, Chen Z, He Y, Li P, et al
    Non-muscle myosin II isoforms orchestrate substrate stiffness sensing to promote cancer cell contractility and migration.
    Cancer Lett. 2022;524:245-258.
    >> Share

  95. ZOU Y, Liu B, Li L, Yin Q, et al
    IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors.
    Cancer Lett. 2022;524:121-130.
    >> Share

    December 2021
  96. WANG Z, Wang F, Ding XY, Li TE, et al
    Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis.
    Cancer Lett. 2021 Dec 17. pii: S0304-3835(21)00632.
    >> Share

  97. CHAI C, Wu HH, Abuetabh Y, Sergi C, et al
    Regulation of the tumor suppressor PTEN in triple-negative breast cancer.
    Cancer Lett. 2021;527:41-48.
    >> Share

  98. TANG W, Xia M, Liao Y, Fang Y, et al
    Exosomes in triple negative breast cancer: From bench to bedside.
    Cancer Lett. 2021;527:1-9.
    >> Share

    November 2021
  99. CHADELLE L, Liu J, Choesmel-Cadamuro V, Karginov AV, et al
    PKCtheta-mediated serine/threonine phosphorylations of FAK govern adhesion and protrusion dynamics within the lamellipodia of migrating breast cancer cells.
    Cancer Lett. 2021 Nov 23. pii: S0304-3835(21)00599.
    >> Share

  100. KHUMUKCHAM SS, Penugurti V, Soni A, Uppala V, et al
    A reciprocal feedback loop between HIF-1alpha and HPIP controls phenotypic plasticity in breast cancer cells.
    Cancer Lett. 2021 Nov 9. pii: S0304-3835(21)00568.
    >> Share

  101. ALRAOUJI NN, Hendrayani SF, Ghebeh H, Al-Mohanna FH, et al
    Osteoprotegerin (OPG) mediates the anti-carcinogenic effects of normal breast fibroblasts and targets cancer stem cells through inhibition of the beta-catenin pathway.
    Cancer Lett. 2021;520:374-384.
    >> Share

  102. LEE O, Bosland MC, Wang M, Shidfar A, et al
    Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
    Cancer Lett. 2021;520:255-266.
    >> Share

    October 2021
  103. WANG SF, Chang YL, Tony Tzeng YD, Wu CL, et al
    Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling.
    Cancer Lett. 2021 Oct 2. pii: S0304-3835(21)00504.
    >> Share

  104. ALSHEIKH HAM, Metge BJ, Ha CM, Hinshaw DC, et al
    Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.
    Cancer Lett. 2021;517:24-34.
    >> Share

    September 2021
  105. XIA M, Zu X, Chen Z, Wen G, et al
    Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance.
    Cancer Lett. 2021 Sep 30. pii: S0304-3835(21)00499.
    >> Share

  106. LI C, Qiu S, Jin K, Zheng X, et al
    Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression.
    Cancer Lett. 2021;523:43-56.
    >> Share

  107. YADAV P, Sharma P, Sundaram S, Venkatraman G, et al
    SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells.
    Cancer Lett. 2021;522:211-224.
    >> Share

    August 2021
  108. ZHANG M, Liu J, Liu G, Xing Z, et al
    Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies.
    Cancer Lett. 2021 Aug 10. pii: S0304-3835(21)00394.
    >> Share

  109. NYATI KK, Hashimoto S, Singh SK, Tekguc M, et al
    The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathway.
    Cancer Lett. 2021;520:295-306.
    >> Share

  110. ZHU Y, Zhang H, Han X, Wang Z, et al
    STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells.
    Cancer Lett. 2021 Aug 1. pii: S0304-3835(21)00380.
    >> Share

    July 2021
  111. MCGARRY DJ, Armstrong G, Castino G, Mason S, et al
    MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours.
    Cancer Lett. 2021 Jul 24. pii: S0304-3835(21)00371.
    >> Share

  112. PENUGURTI V, Khumukcham SS, Padala C, Dwivedi A, et al
    HPIP protooncogene differentially regulates metabolic adaptation and cell fate in breast cancer cells under glucose stress via AMPK and RNF2 dependent pathways.
    Cancer Lett. 2021;518:243-255.
    >> Share

  113. PETRI BJ, Piell KM, South Whitt GC, Wilt AE, et al
    HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
    Cancer Lett. 2021;518:152-168.
    >> Share

  114. XU X, Li N, Wang Y, Yu J, et al
    Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP.
    Cancer Lett. 2021;519:150-160.
    >> Share

  115. MININI M, Senni A, He X, Proietti S, et al
    miR-125a-5p impairs the metastatic potential in breast cancer via IP6K1 targeting.
    Cancer Lett. 2021 Jul 3. pii: S0304-3835(21)00326.
    >> Share

    June 2021
  116. HAN HJ, Sung JY, Kim SH, Yun UJ, et al
    Fibronectin regulates anoikis resistance via cell aggregate formation.
    Cancer Lett. 2021;508:59-72.
    >> Share

  117. SANG X, Li L, Rui C, Liu Y, et al
    Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.
    Cancer Lett. 2021;518:82-93.
    >> Share

  118. REGUA AT, Arrigo A, Doheny D, Wong GL, et al
    Transgenic mouse models of breast cancer.
    Cancer Lett. 2021;516:73-83.
    >> Share

    May 2021
  119. DIMITRAKOPOULOS FI, Kottorou A, Tzezou A
    Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer.
    Cancer Lett. 2021 May 30. pii: S0304-3835(21)00254.
    >> Share

  120. WANG H, Shi Y, Chen CH, Wen Y, et al
    KLF5-induced lncRNA IGFL2-AS1 promotes basal-like breast cancer cell growth and survival by upregulating the expression of IGFL1.
    Cancer Lett. 2021;515:49-62.
    >> Share

  121. LI X, Wang H, Yang X, Wang X, et al
    GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling.
    Cancer Lett. 2021 May 20. pii: S0304-3835(21)00194.
    >> Share

  122. PROVANCE OK, Geanes ES, Lui AJ, Roy A, et al
    Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression.
    Cancer Lett. 2021;514:12-29.
    >> Share

  123. LIGORIO F, Pellegrini I, Castagnoli L, Vingiani A, et al
    Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer.
    Cancer Lett. 2021 May 4. pii: S0304-3835(21)00189.
    >> Share

  124. WANG M, Dai M, Wang D, Tang T, et al
    The long noncoding RNA AATBC promotes breast cancer migration and invasion by interacting with YBX1 and activating the YAP1/Hippo signaling pathway.
    Cancer Lett. 2021 May 2. pii: S0304-3835(21)00191.
    >> Share

    April 2021
  125. VENKATESH J, Wasson MD, Brown JM, Fernando W, et al
    LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack.
    Cancer Lett. 2021 Apr 10. pii: S0304-3835(21)00156.
    >> Share

  126. WANG CJ, Li D, Danielson JA, Zhang EH, et al
    Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
    Cancer Lett. 2021 Apr 1. pii: S0304-3835(21)00149.
    >> Share

    March 2021
  127. KAUL K, Misri S, Ramaswamy B, Ganju RK, et al
    Contribution of the tumor and obese microenvironment to triple negative breast cancer.
    Cancer Lett. 2021 Mar 30. pii: S0304-3835(21)00141.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016